Suppr超能文献

多巴胺D1受体激活可诱导肝癌细胞系HepG2中的硫酸脱氢表雄酮硫酸转移酶(SULT2A1)。

Dopamine D1 receptor activation induces dehydroepiandrosterone sulfotransferase (SULT2A1) in HepG2 cells.

作者信息

Xu Jiao-Jiao, Wang Si-Yuan, Chen Ye, Chen Guang-Ping, Li Zai-Quan, Shao Xue-Yan, Li Liang, Lu Wei, Zhou Tian-Yan

出版信息

Acta Pharmacol Sin. 2014 Jul;35(7):889-98. doi: 10.1038/aps.2014.19. Epub 2014 Jun 9.

Abstract

AIM

Dopamine receptors are present in the nervous system and also widely distributed in the periphery. The aim of this study was to investigate the role of D1 subtype dopamine receptors (DRD1) in the regulation of dehydroepiandrosterone sulfotransferase (SULT2A1) in HepG2 cells.

METHODS

HepG2 cells were treated with DRD1 agonists with or without DRD1 antagonist for 9 d. DRD1 and SULT2A1 mRNA expression, protein expression, and SULT2A1 activity were detected using RT-PCR, Western blotting and HPLC, respectively. The level of cAMP was measured using a commercial kit.

RESULTS

All the 5 DR subtypes (DRD1-DRD5) were found to be expressed in HepG2 cells. Treatment of HepG2 cells with the specific DRD1 agonists SKF82958 (2.5 μmol/L) or SKF38393 (5 and 50 μmol/L) significantly increased the mRNA and protein expression of both DRD1 and SULT2A1, and increased SULT2A1 activity and cAMP levels. These effects were partially blocked by co-treatment with the specific DRD1 antagonist SCH23390 (2.5 μmol/L). In addition, transfection of HepG2 cells with DRD1-specific siRNAs decreased DRD1 mRNA expression by 40%, which resulted in the reduction of SULT2A1 mRNA expression by 60%, protein expression by 40%, and enzyme activity by 20%.

CONCLUSION

DRD1 activation upregulates DRD1 and SULT2A1 expression and SULT2A1 activity in HepG2 cells, suggesting that the DRD1 subtype may be involved in the metabolism of drugs and xenobiotics through regulating SULT2A1.

摘要

目的

多巴胺受体存在于神经系统中,也广泛分布于外周。本研究的目的是探讨D1亚型多巴胺受体(DRD1)在调节HepG2细胞中脱氢表雄酮硫酸转移酶(SULT2A1)中的作用。

方法

用DRD1激动剂处理HepG2细胞9天,同时或不同时使用DRD1拮抗剂。分别使用逆转录聚合酶链反应(RT-PCR)、蛋白质免疫印迹法(Western blotting)和高效液相色谱法(HPLC)检测DRD1和SULT2A1的信使核糖核酸(mRNA)表达、蛋白质表达及SULT2A1活性。使用商业试剂盒测量环磷酸腺苷(cAMP)水平。

结果

发现所有5种DR亚型(DRD1-DRD5)均在HepG2细胞中表达。用特异性DRD1激动剂SKF82958(2.5微摩尔/升)或SKF38393(5和50微摩尔/升)处理HepG2细胞,显著增加了DRD1和SULT2A1的mRNA和蛋白质表达,并增加了SULT2A1活性和cAMP水平。与特异性DRD1拮抗剂SCH23390(2.5微摩尔/升)共同处理可部分阻断这些作用。此外,用DRD1特异性小干扰RNA(siRNAs)转染HepG2细胞,使DRD1 mRNA表达降低40%,导致SULT2A1 mRNA表达降低60%,蛋白质表达降低40%,酶活性降低20%。

结论

DRD1激活上调HepG2细胞中DRD1和SULT2A1的表达以及SULT2A1活性,提示DRD1亚型可能通过调节SULT2A1参与药物和外源性物质的代谢。

相似文献

5

本文引用的文献

7
Dopamine receptor agonists in cardiovascular medicine.多巴胺受体激动剂在心血管医学中的应用。
Trends Cardiovasc Med. 1991 Apr;1(3):103-7. doi: 10.1016/1050-1738(91)90002-V.
8
Phase II drug metabolizing enzymes.II期药物代谢酶
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010 Jun;154(2):103-16. doi: 10.5507/bp.2010.017.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验